2026-04-13T04:06:15Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/117162025-10-24T10:20:32Zcom_2072_378070com_2072_378040col_2072_378092

External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors Esteban, Luis M. Borque Fernando, Ángel Picola Brau, Natalia Muñoz-Rodriguez, Jesus Paesano, Nahuel Miro, Berta Celma, Ana Morote Robles, Juan Pròstata - Càncer - Imatgeria Pròstata - Càncer - Tractament Inhibidors enzimàtics - Ús terapèutic CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Steroid Synthesis Inhibitors::5-alpha Reductase Inhibitors DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de la síntesis esteroidea::inhibidores de la 5-alfa reductasa ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética 5-alpha reductase inhibitor; Predictive model; Prostate cancer Inhibidor de la 5-alfa reductasa; Modelo predictivo; Cáncer de próstata Inhibidor de la 5-alfa reductasa; Model predictiu; Càncer de pròstata Purpose To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). Materials and methods A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2. Results The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783–0.842) and 0.849 (0.806–0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users. Conclusions The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment. This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666). Open Access Funding provided by Universitat Autonoma de Barcelona. 2025-10-24T10:20:32Z 2025-10-24T10:20:32Z 2025-10-24T10:20:32Z 2024-07-16T12:21:35Z 2024-07-16T12:21:35Z 2024-07-10 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/11716 World Journal of Urology;42 https://doi.org/10.1007/s00345-024-05092-0 info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01666 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Springer Scientia